Mobile website
The Treatment of Moderately Advanced Carcinoma with Chemo-Immunotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
A comparison of effectiveness of chemo-immunotherapy (CIT) using LAK/CD3AK 1-2 weeks after TACE in 74 patients with no surgical indication and TACE alone in 41 patients with moderately advanced HCC was carried out. The rates of remission between CIT group and TACE alone group were 72.4% and 40.4%(P<0.05) in stage II HCC and 48.9% and 14.3% (P<0.05) in stage III HCC respectively (P<0.05). The 6 and 12 months survival of stage III HCC and 2 years survival rates of stage II of CIT group were 62.2%,46.0% and 48. 3% respectively, significantly higher than those of TACE alone group (23.8%,9.5% and 15% respectively,P<0.05). The rates of extrahepatic metastasis within 12 month of CIT group was 25.9%, significantly lower than that of TACE alone group(58.1%,P<0.05). The results show chemo-immunotherapy is a rational and effective treatment for moderately advanced HCC.
Keywords:
Project Supported:
Clc Number:
